Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920745 · ClinicalTrials.gov registry record
TriClip CED RWE Study
A clinical trial of Tricuspid Regurgitation, sponsored by Abbott Medical Devices.
- Recruiting
- Registry status
- 2,200
- Enrollment target
- 1
- Study location
NCT06920745: Recruiting study of Tricuspid Regurgitation, sponsored by Abbott Medical Devices.
NCT06920745 is a study of Tricuspid Regurgitation that is actively recruiting participants, run by Abbott Medical Devices. The registered enrollment target is 2,200 participants, above the 406-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (442% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06920745, a study of Tricuspid Regurgitation, is actively recruiting participants, sponsored by Abbott Medical Devices.
- RECRUITING
- Registry status
- 2,200 participants
- Enrollment target
- 1
- Study location
Study Summary
This Coverage with Evidence Development (CED) study evaluates the long-term health outcomes of patients with symptomatic, severe or greater Tricuspid Regurgitation who received a Tricuspid Transcatheter Edge-to-Edge Repair (T-TEER) procedure using the TriClip system.
Primary Outcome
Compare the rate of composite endpoint at 2 years between the treatment and control groups.
Conditions Studied
Interventions
- DEVICE The TriClip System
Study Locations (1)
California
- Abbott - Santa Clara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2025-07-08 |
| Est. Completion | 2032-07 |
What NCT06920745 shows while recruiting
NCT06920745 is an observational study that tracks outcomes without assigning an intervention. Its 2,200 participants enrollment target places it among the larger protocols in the corpus, above the 406-participant average among 17 other Tricuspid Regurgitation trials with a reported enrollment target (442% higher).
The record links to 1 condition, with Tricuspid Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which The TriClip System is the first listed.
NCT06920745 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06920745 about?
NCT06920745 is a clinical study titled "TriClip CED RWE Study". This Coverage with Evidence Development (CED) study evaluates the long-term health outcomes of patients with symptomatic, severe or greater Tricuspid Regurgitation who received a Tricuspid Transcatheter Edge-to-Edge Repair (T-TEER) procedure using the TriClip system.
What is the current status of trial NCT06920745?
This trial is currently recruiting. The enrollment target is 2,200 participants. The study started on 2025-07-08. Estimated completion is 2032-07.
What conditions does trial NCT06920745 study?
This clinical trial studies the following conditions: Tricuspid Regurgitation.
What interventions are being tested in trial NCT06920745?
The interventions under investigation include: The TriClip System (DEVICE).
Who is sponsoring clinical trial NCT06920745?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920745 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tricuspid Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06920745's enrollment target sits among peer trials
2,200 1st of 17 higher than 17 of 17 other Tricuspid Regurgitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tricuspid Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
RECRUITING
-
TTVR Early Feasibility Study
RECRUITING · NA
-
Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
RECRUITING · NA
-
Early Feasibility Study (EFS) Laplace Transcatheter Tricuspid Valve Replacement (TTVR) System
RECRUITING · NA
-
TTVR STRONG Under Coverage With Evidence Development (CED) Study
RECRUITING
-
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI